Development and optimization of an adenovirus production process.
about
Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogensMoving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic virusesCurrent and emerging cell culture manufacturing technologies for influenza vaccines.A serum-free Vero production platform for a chimeric virus vaccine candidateSerum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.Immobilization of 293 cells using porous support particles for adenovirus vector production.Adenovirus vector production using low-multiplicity infection of 293 cells.Efficient amplification of chimeric adenovirus 5/40S vectors carrying the short fiber protein of Ad40 in suspension cell culturesA rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers.Characterization of a permissive epitope insertion site in adenovirus hexonEvaluation of novel large cut-off ultrafiltration membranes for adenovirus serotype 5 (Ad5) concentration.Versatility of gene therapy vectors through viruses.Downstream processing of viral vectors and vaccines.Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications.Use of adenoviral vectors as veterinary vaccines.Adenovirus-vectored novel African Swine Fever Virus antigens elicit robust immune responses in swine.Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.Flow-dependent entrapment of large bioparticles in porous process mediaNew insights on adenovirus as vaccine vectors.Pancreatic cancer: gene therapy approaches and gene delivery systems.Downstream processing of cell culture-derived virus particles.Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials.Future Prospects for the Development of Cost-Effective Adenovirus Vaccines.Human amniocyte-derived cells are a promising cell host for adenoviral vector production under serum-free conditions.Impact of adenovirus life cycle progression on the generation of canine helper-dependent vectors.Bioprocess development for canine adenovirus type 2 vectors.Induction of Robust Immune Responses in Swine by Using a Cocktail of Adenovirus-Vectored African Swine Fever Virus Antigens.Cell culture processes for the production of viral vectors for gene therapy purposes.Advancements in the design and scalable production of viral gene transfer vectors.Improved poliovirus D-antigen yields by application of different Vero cell cultivation methodsImproved particle counting and size distribution determination of aggregated virus populations by asymmetric flow field-flow fractionation and multiangle light scattering techniques.Gene therapy for Parkinson's disease
P2860
Q26750912-9BD67E06-F3B3-47BD-8FA1-6546D0F05743Q26752807-B0C5F8E7-A0F9-435B-8843-505ECBC94579Q30373128-FEF87E28-ED45-4300-90F1-84080EC4C44AQ30462034-411B924E-F809-4AE1-9D9E-ECFD40C19AA8Q30474419-BCEC1550-5E4C-43CA-A4FD-164CC2AB12C8Q30474633-820B118A-0C0E-4A1F-9996-FCF9E1F69E39Q30482293-7CA8E186-8548-497B-80C1-1F14144EAE31Q34364465-72ACAB74-8AE8-43D6-9393-152B3B49177DQ34527371-EF99D564-00C8-4D2E-B298-0AB993C49AE6Q34648067-EA73BF90-BA38-4DA2-81F1-7467BA82BA69Q35535220-7BC6DF25-33B3-4377-9941-FBDFBD83EBB8Q36150489-F3382635-374C-4BE0-8605-53F6FFBCE11EQ36288881-8EAAC8FA-9ECA-4618-96B0-84C3AD82EF2FQ36288920-34B75110-2F9E-4CF8-B056-58AD39221EB9Q36288927-828FE805-B283-4C05-A38E-84343264D9A1Q36365710-993E258E-837F-4D9E-B932-A04EB7AE5D26Q36960666-4F3D5FF9-7CB8-417E-B426-D9F3378E02D2Q37435026-6A34F6B3-4871-46E4-B70F-CAE1E7ADEA0DQ37513550-98B9E1D0-7D97-45E8-A3BB-04531A77E178Q37621562-28724580-24BC-4AC5-A5D5-FF5323545E19Q37944322-CEF09D81-5B43-414F-A314-2F3C46CB4287Q38443390-732944D9-CFF8-4A51-9853-C7FD6D0E0D61Q38728732-3F37FEA5-7B42-4119-82B8-3DE255A46C66Q38878799-10842052-94CB-4DC0-A3F8-75C0F6989C7FQ38945731-F7310D51-C48A-428F-8C5E-733BF5107438Q39319692-424EEB26-9E58-4E78-910D-93A174D52DFCQ40088830-0D040A3B-B4EB-4367-A310-5EA00D9CCB9FQ41856876-0832A2B2-FF6D-4A72-8E66-2338D2FA60D2Q41931475-BB3B2F34-C6AC-462F-AB00-F303A6D4FF19Q42234547-E8067008-13D7-48A7-BA9A-6401481988BEQ45369277-4364E3D1-74BE-49CF-8063-24B9BBD3C376Q58913419-16E7DD7B-E862-4712-9EC2-9EFCE6CBC6B4
P2860
Development and optimization of an adenovirus production process.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Development and optimization of an adenovirus production process.
@ast
Development and optimization of an adenovirus production process.
@en
type
label
Development and optimization of an adenovirus production process.
@ast
Development and optimization of an adenovirus production process.
@en
prefLabel
Development and optimization of an adenovirus production process.
@ast
Development and optimization of an adenovirus production process.
@en
P356
P1476
Development and optimization of an adenovirus production process.
@en
P2093
Amine Kamen
Olivier Henry
P304
P356
10.1002/JGM.503
P478
P577
2004-02-01T00:00:00Z